Advertisement

Early Breast Cancer

  • T. Dragovich
  • O. Olopade
Chapter
  • 109 Downloads

Abstract

Breast cancer remains a major health problem in the United States and other industrialized nations in spite of recent advances in its detection and treatment. Significant progress has been made through decades of basic research and clinical trials, but many questions remain unanswered. The purpose of this chapter is to summarize current information on the treatment of early breast cancer (i.e., breast cancer in which all clinically apparent disease can be removed surgically). The other topics will be covered as much as they are relevant to therapeutic decision making. The treatment of locally advanced and metastatic breast cancer will be addressed in the next chapter.

Keywords

Breast Cancer Sentinel Node Breast Cancer Risk Clin Oncol Axillary Node Dissection 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Forbes JF (1997) The incidence of breast cancer: the global burden, public health considerations. Semin Oncol 24: S120–S135Google Scholar
  2. 2.
    Greenlee RT, Hill-Harmon MB, Taylor M, Thun M (2001) Cancer statistics 2001. CA Cancer J Clin 51:15–36PubMedCrossRefGoogle Scholar
  3. 3.
    Ang P, Garber JE (2001) Genetic susceptibility for breast cancer-risk assessment and counseling. Semin Oncol 28: 419–433PubMedCrossRefGoogle Scholar
  4. 4.
    Willett WC, Stampfer MJ, Colditz GA et al (1987) Moderate alcohol consumption and the risk of breast cancer. N Engl J Med 316:1174–1179PubMedCrossRefGoogle Scholar
  5. 5.
    Ambrosone CB, Freudenheim JL, Graham S et al (1996) Cigarette smoking, N-Acetyltransferase 2 genetic polymorphisms, and breast cancer risk. JAMA 276:1494–1501PubMedCrossRefGoogle Scholar
  6. 6.
    American Joint Committee on Cancer (AJCC) (1997) Cancer staging manual, 5th edn. Lippincott-Raven, PhiladelphiaGoogle Scholar
  7. 7.
    Donegan WL (1997) Tumor-related prognostic factors for breast cancer. CA Cancer J Clin 47:28–51PubMedCrossRefGoogle Scholar
  8. 8.
    Rosen PP, Groshen S, Saigo PE et al (1989) Pathological prognostic factors in stage 1 (T1 NO M0) and stage II (T1 N1 M0) breast carcinomas: a study of 644 patients with median follow-up of 18 years. J Clin Oncol 7:1239–1251PubMedGoogle Scholar
  9. 9.
    Bloom HJG, Richardson WW (1957) Histologic grading and prognosis in breast cancer. Br J Cancer XI:359–377CrossRefGoogle Scholar
  10. 10.
    Yamauchi H, Stearns V, Hayes DF (2001) When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol 19:2334–2351PubMedGoogle Scholar
  11. 11.
    Foekens JA, Schmitt M, van Putten WL et al (1994) Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol 12:1648–1658PubMedGoogle Scholar
  12. 12.
    Braun S, Pantel K, Muller P et al (2000) Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med 342:525–533PubMedCrossRefGoogle Scholar
  13. 13.
    Piccart MJ, Di Leo A, Hamilton A (2000) HER-2, a “predictive” factor ready to use in the daily management of breast cancer patients? Eur J Cancer 36:1755–1761PubMedCrossRefGoogle Scholar
  14. 14.
    Gail MH, Brinton LA, Byar DP et al (1989) Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81:1879–1886PubMedCrossRefGoogle Scholar
  15. 15.
    Fisher B, Costantino JP, Wickerham DL et al (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-l Study. J Natl Cancer Inst 90:1371–1388PubMedCrossRefGoogle Scholar
  16. 16.
    Powles T, Eeles R, Ashley S et al (1998) Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomized chemoprevention trial. Lancet 352:98–101PubMedGoogle Scholar
  17. 17.
    Veronesi U, Maisonneuve P, Costa A et al (1998) Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomized trial among hysterectomized women. Italian Tamoxifen Prevention Study. Lancet 352: 93–97PubMedGoogle Scholar
  18. 18.
    Ernster VL, Barclay J, Kerlikowske K et al (1996) Incidence of and treatment of ductal carcinoma in situ of the breast. JAMA 275:913–918PubMedCrossRefGoogle Scholar
  19. 19.
    Fisher B, Anderson S (1994) Conservative surgery for the management of invasive and noninvasive carcinoma of the breast: NSABP trials. World J Surg 18:63–69PubMedCrossRefGoogle Scholar
  20. 20.
    Goldschmidt RA, Victor TA (1996) Lobular carcinoma in situ of the breast. Semin Surg Oncol 12:314–320PubMedCrossRefGoogle Scholar
  21. 21.
    Fisher B, Anderson S, Redmond CK et al (1995) Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 333:1456–1461PubMedCrossRefGoogle Scholar
  22. 22.
    Veronesi U, Saccozzi R, Del Vecchio M et al (1981) Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast. N Engl J Med 305:6–11PubMedCrossRefGoogle Scholar
  23. 23.
    Moore MP, Kinne DW (1997) Axillary lymphadenectomy: a diagnostic and therapeutic procedure. J Surg Oncol 66:2–6PubMedCrossRefGoogle Scholar
  24. 24.
    Albertini JJ, Lyman GH, Cox C et al (1996) Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA 276:1818–1822PubMedCrossRefGoogle Scholar
  25. 25.
    Cox CE, Pendas S, Cox JM et al (1998) Guidelines for sentinel node biopsy and lymphatic mapping of patients with breast cancer. Ann Surg 227:645–653PubMedCrossRefGoogle Scholar
  26. 26.
    Early Breast Cancer Trialists Collaborative Group (1995) Effects of radiotherapy and surgery in early breast cancer: an overview of randomized trials. N Engl J Med 333:1444–1455CrossRefGoogle Scholar
  27. 27.
    Overgaard M, Hansen PS, Overgaard J et al (1997) Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. N Engl J Med 337:949–955PubMedCrossRefGoogle Scholar
  28. 28.
    Ragaz J, Jackson SM, Le N et al (1997) Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med 337:956–962PubMedCrossRefGoogle Scholar
  29. 29.
    Buzdar AU, Hortobagyi G (1998) Update on endocrine therapy for breast cancer. Clin Cancer Res 4:527–534PubMedGoogle Scholar
  30. 30.
    Early Breast Cancer Trialists Collaborative Group (1998) Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 351:1451–1467CrossRefGoogle Scholar
  31. 31.
    Carcangiu ML (1994) RE: endometrial cancer in tamoxifentreated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Can Inst 86:1251–1252CrossRefGoogle Scholar
  32. 32.
    Assikis VJ, Jordan VC (1997) Risks and benefits of tamoxifen therapy. Oncology (Huntingt) 11:S21–S23Google Scholar
  33. 33.
    Swedish Breast Cancer Cooperative Group (1996) Randomized trial of 2 versus 5 years of adjuvant tamoxifen in postmenopausal women with early-stage breast cancer. J Natl Can Inst 88:1543–1549CrossRefGoogle Scholar
  34. 34.
    Early Breast Cancer Trialists’ Collaborative Group (2000) Ovarian ablation in early breast cancer: Update. Cochrane Database Syst Rev (3) CD000485Google Scholar
  35. 35.
    Fisher B, Fisher ER, Redmond C et al (1986) Ten-year results from the National Surgical Adjuvant Breast and Bowel Project (NSABP) clinical trial evaluating the use of L-Phenylalanine mustard (L-PAM) in the management of primary breast cancer. J Clin Oncol 4:929–941PubMedGoogle Scholar
  36. 36.
    Bonnadonna G, Rossi A, Valagussa P (1985) Adjuvant CMF chemotherapy in operable breast cancer: ten years later. World J Surg 9:707–713CrossRefGoogle Scholar
  37. 37.
    Fisher B, Dignam J, Mamounas E et al (1996) Sequential methotrexate and fluorouracil for the treatment of nodenegative breast cancer patients with estrogen receptor-negative tumors; eight-year results from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate and fluorouracil. J Clin Oncol 14:1982–1992PubMedGoogle Scholar
  38. 38.
    Early Breast Cancer Trialists Collaborative Group (1998) Polychemotherapy for early breast cancer: and overview of the randomized trials. Lancet 352:930–942CrossRefGoogle Scholar
  39. 39.
    Fisher B, Brown AM, Dimitrov MV et al (1990) Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate and fluorouracil in positive breast cancer patients with tamoxifen-nonresponsive tumors: results from (NSABP) B-15. J Clin Oncol 8:1483–1496PubMedGoogle Scholar
  40. 40.
    Bonnadonna G, Zambetti M, Valagussa P (1995) Sequential or alternative doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results. JAMA 273:542–547CrossRefGoogle Scholar
  41. 41.
    Henderson IC, Berry D, Demetri G et al (1998) Improved disease-free (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients (Pts) with node-positive primary breast cancer (BC) (abstract no. 390A). Proc Am Soc Clin Oncol 17:101AGoogle Scholar
  42. 42.
    Fisher B, Brown A, Mamounas E et al (1997) Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15:2483–2493PubMedGoogle Scholar
  43. 43.
    Rodenhuis S, Richel DJ, van der Wall E et al (1998) Randomized trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement. Lancet 352: 515–521PubMedCrossRefGoogle Scholar
  44. 44.
    Peters WP, Ross M, Vredenburgh JJ et al (1993) High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 11:1132–1143PubMedGoogle Scholar
  45. 45.
    Hortobagyi G, Buzdar AU, Theriault RL et al (2000) Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. J Natl Cancer Inst 92:225–233PubMedCrossRefGoogle Scholar
  46. 46.
    Baynes RD, Dansey RD, Klein JL et al (2001) High-dose chemotherapy and hematopoietic stem cell transplantation for breast cancer: past or future? Semin Oncol 28:377–388PubMedCrossRefGoogle Scholar
  47. 47.
    Breast Cancer Surveillance Expert Panel (1997) Recommended breast cancer surveillance guidelines. J Clin Oncol 15:2149–2156Google Scholar
  48. 48.
    Nathanson KN, Wooster R, Weber BL (2001) Breast cancer genetics: what we know and what we need. Nat Med 7:552–556PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2003

Authors and Affiliations

  • T. Dragovich
  • O. Olopade

There are no affiliations available

Personalised recommendations